Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more ...

where he will address the pricing of Novo Nordisk’s widely popular diabetes and weight loss drugs. Senator Bernie Sanders, chair of the Health, Education, Labor and Pensions (HELP) Committee ...

Novo Nordisk ... the company to force Novo Nordisk’s North America operations chief, Doug Langa, to be available to answer questions at the Health, Education, Labor and Pensions (HELP ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future. Vertex is a better pick than Novo right now for one key reason.

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...